Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6UX04
UPID:
CWC27_HUMAN
Alternative names:
Antigen NY-CO-10; Probable inactive peptidyl-prolyl cis-trans isomerase CWC27 homolog; Serologically defined colon cancer antigen 10
Alternative UPACC:
Q6UX04; O60529; O60530; Q96EM3
Background:
Spliceosome-associated protein CWC27 homolog, also known as Antigen NY-CO-10 and Serologically defined colon cancer antigen 10, plays a crucial role in pre-mRNA splicing as part of the spliceosome. Despite its probable inactive PPIase status, it significantly contributes to the splicing of U12-type introns, underscoring its importance in RNA processing.
Therapeutic significance:
Linked to Retinitis pigmentosa with or without skeletal anomalies, a disease marked by retinal degeneration and neurologic defects, understanding the role of Spliceosome-associated protein CWC27 homolog could open doors to potential therapeutic strategies.